Clinical Formulation Bridging of Gefapixant, a P2X3‐Receptor Antagonist, for the Treatment of Chronic Cough
Author:
Affiliation:
1. Merck & Co., Inc. Kenilworth New Jersey USA
2. CuraSen Therapeutics San Carols California USA
3. Afferent Pharmaceuticals, Inc. San Mateo California USA
Funder
Merck Sharp and Dohme
Publisher
Wiley
Subject
Pharmacology (medical),Pharmaceutical Science
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.1105
Reference17 articles.
1. Diagnosis and Management of Cough Executive Summary
2. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children
3. Vagal Afferent Innervation of the Airways in Health and Disease
4. Blocking voltage-gated sodium channels as a strategy to suppress pathological cough
5. In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The discovery and development of gefapixant as a novel antitussive therapy;Expert Opinion on Drug Discovery;2024-08-13
2. Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough;Drugs;2024-06-21
3. Physiologically Based Biopharmaceutics Modeling for Gefapixant IR Formulation Development and Defining the Bioequivalence Dissolution Safe Space;The AAPS Journal;2024-06-11
4. Single‐ and Multiple‐Dose Pharmacokinetics of Gefapixant (MK‐7264), a P2X3 Receptor Antagonist, in Healthy Adults;The Journal of Clinical Pharmacology;2024-04-23
5. Gefapixant for Chronic Cough;JAMA;2024-02-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3